1
|
Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors. Eur J Med Chem 2020; 200:112448. [DOI: 10.1016/j.ejmech.2020.112448] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 05/09/2020] [Accepted: 05/09/2020] [Indexed: 01/02/2023]
|
2
|
Romagnoli R, Prencipe F, Oliva P, Baraldi S, Baraldi PG, Schiaffino Ortega S, Chayah M, Kimatrai Salvador M, Lopez-Cara LC, Brancale A, Ferla S, Hamel E, Ronca R, Bortolozzi R, Mariotto E, Mattiuzzo E, Viola G. Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2- d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors. J Med Chem 2019; 62:1274-1290. [PMID: 30633509 DOI: 10.1021/acs.jmedchem.8b01391] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
The clinical evidence for the success of tyrosine kinase inhibitors in combination with microtubule-targeting agents prompted us to design and develop single agents that possess both epidermal growth factor receptor (EGFR) kinase and tubulin polymerization inhibitory properties. A series of 6-aryl/heteroaryl-4-(3',4',5'-trimethoxyanilino)thieno[3,2- d]pyrimidine derivatives were discovered as novel dual tubulin polymerization and EGFR kinase inhibitors. The 4-(3',4',5'-trimethoxyanilino)-6-( p-tolyl)thieno[3,2- d]pyrimidine derivative 6g was the most potent compound of the series as an antiproliferative agent, with half-maximal inhibitory concentration (IC50) values in the single- or double-digit nanomolar range. Compound 6g bound to tubulin in the colchicine site and inhibited tubulin assembly with an IC50 value of 0.71 μM, and 6g inhibited EGFR activity with an IC50 value of 30 nM. Our data suggested that the excellent in vitro and in vivo profile of 6g may be derived from its dual inhibition of tubulin polymerization and EGFR kinase.
Collapse
Affiliation(s)
- Romeo Romagnoli
- Dipartimento di Scienze Chimiche e Farmaceutiche , Università degli Studi di Ferrara , Via Luigi Borsari 46 , 44121 Ferrara , Italy
| | - Filippo Prencipe
- Dipartimento di Scienze Chimiche e Farmaceutiche , Università degli Studi di Ferrara , Via Luigi Borsari 46 , 44121 Ferrara , Italy
| | - Paola Oliva
- Dipartimento di Scienze Chimiche e Farmaceutiche , Università degli Studi di Ferrara , Via Luigi Borsari 46 , 44121 Ferrara , Italy
| | - Stefania Baraldi
- Dipartimento di Scienze Chimiche e Farmaceutiche , Università degli Studi di Ferrara , Via Luigi Borsari 46 , 44121 Ferrara , Italy
| | - Pier Giovanni Baraldi
- Dipartimento di Scienze Chimiche e Farmaceutiche , Università degli Studi di Ferrara , Via Luigi Borsari 46 , 44121 Ferrara , Italy
| | - Santiago Schiaffino Ortega
- Departamento de Química Farmacéutica y Orgánica , Facultad de Farmacia , Campus de Cartuja s/n , 18071 Granada , Spain
| | - Mariem Chayah
- Departamento de Química Farmacéutica y Orgánica , Facultad de Farmacia , Campus de Cartuja s/n , 18071 Granada , Spain
| | - Maria Kimatrai Salvador
- Departamento de Química Farmacéutica y Orgánica , Facultad de Farmacia , Campus de Cartuja s/n , 18071 Granada , Spain
| | - Luisa Carlota Lopez-Cara
- Departamento de Química Farmacéutica y Orgánica , Facultad de Farmacia , Campus de Cartuja s/n , 18071 Granada , Spain
| | - Andrea Brancale
- School of Pharmacy and Pharmaceutical Sciences , Cardiff University , King Edward VII Avenue , Cardiff CF10 3NB , U.K
| | - Salvatore Ferla
- School of Pharmacy and Pharmaceutical Sciences , Cardiff University , King Edward VII Avenue , Cardiff CF10 3NB , U.K
| | - Ernest Hamel
- Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research , National Cancer Institute, National Institutes of Health , Frederick , Maryland 21702 , United States
| | - Roberto Ronca
- Dipartimento di Medicina Molecolare e Traslazionale Unità di Oncologia Sperimentale ed Immunologia , Università di Brescia , 25123 Brescia , Italy
| | - Roberta Bortolozzi
- Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia , Università di Padova , 35131 Padova , Italy
| | - Elena Mariotto
- Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia , Università di Padova , 35131 Padova , Italy
| | - Elena Mattiuzzo
- Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia , Università di Padova , 35131 Padova , Italy
| | - Giampietro Viola
- Dipartimento di Salute della Donna e del Bambino, Laboratorio di Oncoematologia , Università di Padova , 35131 Padova , Italy.,Istituto di Ricerca Pediatrica (IRP) , Corso Stati Uniti 4 , 35128 Padova , Italy
| |
Collapse
|
3
|
Lyu M, Zhou Z, Wang X, Lv H, Wang M, Pan G, Wang Y, Fan G, Gao X, Feng Y, Zhu Y. Network Pharmacology-Guided Development of a Novel Integrative Regimen to Prevent Acute Graft-vs.-Host Disease. Front Pharmacol 2018; 9:1440. [PMID: 30618740 PMCID: PMC6300759 DOI: 10.3389/fphar.2018.01440] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Accepted: 11/22/2018] [Indexed: 01/20/2023] Open
Abstract
Lapses in the graft-vs.-host disease (GVHD) prophylaxis and side effects of current standard care following allogeneic hematopoietic stem cell transplantation (allo-HSCT) call for novel regimens. Traditional approaches targeting T cells showed limited success in preventing acute GVHD (aGVHD). System medicine showed promising results treating complex diseases such as sepsis and multi-organ dysfunction syndrome (MODS). Adapting established network pharmacology analysis methods, we aimed to develop novel integrative regimens to prevent aGVHD. Our network pharmacology analysis predicted that Xuebijing injection (XBJ) targets a series of key node proteins in aGVHD network. It also unveiled that Salviae miltiorrhizae (Danshen), an herb in Xuebijing formula, which prevented aGVHD in rats, shares five out of six key GVHD node proteins targeted by XBJ. Interestingly, network pharmacology analysis indicated Xuebijing may share multiple aGVHD targets with Cyclosporin A (CsA), a first-line drug for preventing aGVHD in the clinic. Based on current information, we hypothesized that combination of XBJ and CsA may yield superior results in aGVHD prevention than either drug alone. We performed in vitro and in vivo assays to validate the predictions by the network pharmacology analysis. In vitro assays revealed XBJ prevented platelet aggregation and NF-κB nuclear translocation in macrophages. XBJ also promoted angiogenesis in tube-formation assay. Importantly, the combination of CsA and XBJ was effective in rescuing mice subjected to lethal GVHD. XBJ contributed to the rescue through preventing NF-κB nuclear translocation, attenuating inflammation and maintaining viability of macrophages. Overall, network pharmacology is a powerful tool to develop novel integrative regimens. Combination of XBJ and CsA may shed light on preventing aGVHD.
Collapse
Affiliation(s)
- Ming Lyu
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.,Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, TEDA, Tianjin, China
| | - Zhengcan Zhou
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Xiaoming Wang
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.,Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, TEDA, Tianjin, China
| | - Hong Lv
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.,Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, TEDA, Tianjin, China
| | - Mei Wang
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
| | - Guixiang Pan
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.,Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, TEDA, Tianjin, China
| | - Yuefei Wang
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.,Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, TEDA, Tianjin, China
| | - Guanwei Fan
- Medical Experiment Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Xiumei Gao
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Yuxin Feng
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.,Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, TEDA, Tianjin, China
| | - Yan Zhu
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.,Research and Development Center of TCM, Tianjin International Joint Academy of Biotechnology & Medicine, TEDA, Tianjin, China
| |
Collapse
|
4
|
Porcù E, Maule F, Boso D, Rampazzo E, Barbieri V, Zuccolotto G, Rosato A, Frasson C, Viola G, Della Puppa A, Basso G, Persano L. BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. Cell Death Differ 2018; 25:1808-1822. [PMID: 29977042 DOI: 10.1038/s41418-018-0149-9] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2017] [Revised: 05/21/2018] [Accepted: 06/06/2018] [Indexed: 02/07/2023] Open
Abstract
Glioblastoma multiforme (GBM) is a highly vascularized and aggressive brain tumor, with a strong ability to disseminate and invade the surrounding parenchyma. In addition, a subpopulation of GBM stem cells has been reported to possess the ability to transdifferentiate into tumor-derived endothelial cells (TDECs), supporting the resistance to anti-angiogenic treatments of newly formed blood vessels. Bone Morphogenetic Protein 9 (BMP9) is critically involved in the processes of cancer cell differentiation, invasion and metastasis, representing a potential tool in order to impair the intrinsic GBM aggressiveness. Here we demonstrate that BMP9 is able to trigger the activation of SMADs in patient-derived GBM cells, and to strongly inhibit proliferation and invasion by reducing the activation of PI3K/AKT/MAPK and RhoA/Cofilin pathways, respectively. Intriguingly, BMP9 treatment is sufficient to induce a strong differentiation of GBM stem-like cells and to significantly counteract the already reported process of GBM cell transdifferentiation into TDECs not only in in vitro mimicked TDEC models, but also in vivo in orthotopic xenografts in mice. Additionally, we describe a strong BMP9-mediated inhibition of the whole angiogenic process engaged during GBM tumor formation. Based on these results, we believe that BMP9, by acting at multiple levels against GBM cell aggressiveness, can be considered a promising candidate, to be further developed, for the future therapeutic management of GBM.
Collapse
Affiliation(s)
- Elena Porcù
- Department of Woman and Children Health, University of Padova, Padova, Italy
| | - Francesca Maule
- Department of Woman and Children Health, University of Padova, Padova, Italy
| | - Daniele Boso
- Department of Woman and Children Health, University of Padova, Padova, Italy
| | - Elena Rampazzo
- Department of Woman and Children Health, University of Padova, Padova, Italy
| | - Vito Barbieri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.,Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - Gaia Zuccolotto
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
| | - Antonio Rosato
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.,Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy
| | - Chiara Frasson
- Department of Woman and Children Health, University of Padova, Padova, Italy.,Istituto di Ricerca Pediatrica - Città della Speranza - IRP, Padova, Italy
| | - Giampietro Viola
- Department of Woman and Children Health, University of Padova, Padova, Italy
| | | | - Giuseppe Basso
- Department of Woman and Children Health, University of Padova, Padova, Italy
| | - Luca Persano
- Istituto di Ricerca Pediatrica - Città della Speranza - IRP, Padova, Italy.
| |
Collapse
|
5
|
Sherbet G. Suppression of angiogenesis and tumour progression by combretastatin and derivatives. Cancer Lett 2017; 403:289-295. [DOI: 10.1016/j.canlet.2017.06.032] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 06/10/2017] [Accepted: 06/28/2017] [Indexed: 12/17/2022]
|
6
|
Shu C, Wang J. The relationship between MRI quantitative parameters and the expression of hypoxia inducible factor-1 alpha in cerebral astrocytoma. Clin Neurol Neurosurg 2016; 153:14-19. [PMID: 28006727 DOI: 10.1016/j.clineuro.2016.11.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Revised: 10/31/2016] [Accepted: 11/14/2016] [Indexed: 12/31/2022]
Abstract
OBJECTIVE Astrocytoma is the common type of glioma. But the MRI scanning for astrocytoma preoperation pathological diagnosis is not exact. The purpose of this study was to use the MRI multi quantitative parameters to improve the diagnosis of astrocytoma and exploit their molecular mechanism related to the expression of HIF-1α. METHODS Superconducting MR scanner and its work station were used to calculate the MRI multi quantitative parameters of the selected patients in this experiment. Scion Image Beta4.03 software was used to get the cellular density of tumor tissue. The expression of HIF-1α in astrocytoma specimens was detected by immunohistochemistry method. The correlation of MRI multi quantitative parameters and the expression of HIF-1α was analyzed by statistical software. RESULT The values of ADC, RSIGd, EP, EI, cellular density and the expression of HIF-1α were changed with the malignant degree of astrocytoma to some extent, but not every quantitative parameter was related to the expression of HIF-1α. CONCLUSION The MRI multi quantitative parameters binding with conventional MRI imaging can significantly raise the diagnostic accuracy of astrocytoma preoperatively. MRI features could indirectly reflect the biological behavior of astrocytoma. The peritumoral edema can't be explained by only one theory.
Collapse
Affiliation(s)
- Chang Shu
- Medical College of Nankai University, Tianjin, 300071, China.
| | - Jinhuan Wang
- Medical College of Nankai University, Tianjin, 300071, China; Department of Neurosurgery, Tianjin Huan Hu Hospital, Tianjin, 300060, China.
| |
Collapse
|